Maarten van der Doelen
Chapter 6
A
B
100
100
Normal baseline ALP Elevated baseline ALP
Subgroup 1-3 Subgroup 4
90
90
80
80
70
70
60
60
50
50
40
40
30 Overall survival (%)
30 Overall survival (%)
20
20
10
10
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 0 Patients at risk Normal ALP 67 62 52 38 32 20 16 12 9 5 2 2 1 1 0 Elevated ALP 113 85 50 28 20 13 10 7 3 3 1 0 0 0 0 Months since start of radium-223
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 0 Patients at risk Subgroup 1 -3 139 123 90 61 49 31 24 17 11 8 3 2 1 1 0 Subgroup 4 33 22 10 4 2 1 1 1 0 0 0 0 0 0 0 Months since start of radium-223
D
C
100
100
Subgroup 1-3 Subgroup 4
Subgroup 1-3 Subgroup 4
90
90
80
80
70
70
60
60
50
50
40
40
30
30
ALP progression (%)
Skeletal-related event (%)
20
20
10
10
0
0
0
3
6
9
12
15
24
27
30
0
6
12
18
24
30
36
42
48
54
Months since start of radium-223
Months since start of radium-223
Patients at risk Subgroup 1 -3 139 Subgroup 4 33
118
50
16
3 0
1 0
1 0
0 0
Subgroup 1 -3 139 Subgroup 4 33
94 12
56
33
21
10
6 0
4 0
1 0
0 0
14
5
0
5
2
1
1
Figure 2. Kaplan-Meier curves. A. Overall survival, comparing the patients with normal baseline ALP levels (subgroups 1-2) to patients with elevated baseline ALP levels (subgroups 3-4). B. Overall survival, comparing the patients in subgroups 1-3 to the patients with elevated baseline ALP without ≥10% ALP decline after the first injection (subgroup 4). C. Time to ALP progression, comparing the patients in subgroup 1-3 to patients with elevated baseline ALP without ≥10% ALP decline after the first injection (subgroup 4). D. Time to first skeletal-related event, comparing the patients in subgroup 1-3 to patients with elevated baseline ALP without ≥10% ALP decline after the first injection (subgroup 4).
160
Made with FlippingBook - professional solution for displaying marketing and sales documents online